Rapid-onset antidepressant action of ketamine: Potential revolution in understanding and future pharmacologic treatment of depression

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 2, 2015, Pages 125-130

  Drewniany, E ^a   Han, J ^a   Hancock, C ^a   Jones, R L ^a   Lim, J ^a   Nemat Gorgani, N ^a   Sperry, J K ^a   Yu, H J ^a   Raffa, R B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

antidepressant; ketamine; major depressive disorder (MDD); mechanism of action

Indexed keywords

KETAMINE; SEROTONIN; SEROTONIN TRANSPORTER; ANTIDEPRESSANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALLELE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHROMOSOME 17; COGNITIVE THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG THERAPY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; NONHUMAN; PREVALENCE; RELAPSE; SUICIDE ATTEMPT; UNITED STATES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DRUG SCREENING;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84924116093     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12238     Document Type: Article

References (74)

1. Covvey JR, Crawford AN, Lowe DK,. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother, 2012; 46: 117-123.
2. Murrough JW,. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther, 2012; 91: 303-309.
3. Hasselmann HW,. Ketamine as antidepressant? Current state and future perspectives. Curr Neuropharmacol, 2014; 12: 57-70.
4. Andrade L, Caraveo-Anduaga JJ, Berglund P, et al,. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res, 2003; 12: 3-21.
5. Vos T, Flaxman AD, Naghavi M, et al,. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012; 380: 2163-2196.
6. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE,. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005; 62: 593-602.
7. Murphy JM, Laird NM, Monson RR, Sobol AM, Leighton AH,. A 40-year perspective on the prevalence of depression: the Stirling County Study. Arch Gen Psychiatry, 2000; 57: 209-215.
8. Kuehner C,. Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr Scand, 2003; 108: 163-174.
9. Eaton WW, Anthony JC, Gallo J, et al,. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The baltimore epidemiologic catchment area follow-up. Arch Gen Psychiatry, 1997; 54: 993-999.
10. Caspi A, Sugden K, Moffitt TE, et al,. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 2003; 301: 386-389.
11. Gelernter J, Pakstis AJ, Kidd KK,. Linkage mapping of serotonin transporter protein gene SLC6A4 on chromosome 17. Hum Genet, 1995; 95: 677-680.
12. March J, Silva S, Petrycki S, et al,. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 2004; 292: 807-820.
13. Reinecke MA, Ryan NE, DuBois DL,. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry, 1998; 37: 26-34.
14. Coelho HF, Canter PH, Ernst E,. Mindfulness-based cognitive therapy: evaluating current evidence and informing future research. J Consult Clin Psychol, 2007; 75: 1000-1005.
15. Weersing VR, Walker PN,. Review: cognitive behavioural therapy for adolescents with depression. Evid Based Ment Health, 2008; 11: 76.
16. Paykel ES,. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol, 2007; 10: 131-136.
17. Simon GE, Savarino J,. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry, 2007; 164: 1029-1034.
18. Fournier JC, DeRubeis RJ, Hollon SD, et al,. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA, 2010; 303: 47-53.
19. Khan A, Faucett J, Lichtenberg P, Kirsch I, Brown WA,. A systematic review of comparative efficacy of treatments and controls for depression. PLoS ONE, 2012; 7: e41778.
20. Fava M, Rush AJ, Alpert JE, et al,. Difference in treatment outcome in outpatients with anxious vs. nonanxious depression: a STAR∗D report. Am J Psychiatry, 2008; 165: 342-351.
21. Trivedi MH, Fava M, Wisniewski SR, et al,. Medication augmentation after the failure of SSRIs for depression. N Engl J Med, 2006; 354: 1243-1252.
22. Group UER. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, 2003; 361: 799-808.
23. Morgan CJ, Curran HV,. Independent scientific committee on D ketamine use: a review. Addiction, 2012; 107: 27-38.
24. Rigby M, Le Bourdelles B, Heavens RP, et al,. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience, 1996; 73: 429-447.
25. Deschwanden A, Karolewicz B, Feyissa AM, et al,. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry, 2011; 168: 727-734.
26. Price RB, Shungu DC, Mao X, et al,. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry, 2009; 65: 792-800.
27. Yuksel C, Ongur D,. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry, 2010; 68: 785-794.
28. Murrough JW, Perez AM, Pillemer S, et al,. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, 2013; 74: 250-256.
29. aan het Rot M, Collins KA, Murrough JW, et al,. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry, 2010; 67: 139-145.
30. Berman RM, Cappiello A, Anand A, et al,. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000; 47: 351-354.
31. Zarate CA Jr, Singh JB, Carlson PJ, et al,. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006; 63: 856-864.
32. Ibrahim L, Diazgranados N, Franco-Chaves J, et al,. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology, 2012; 37: 1526-1533.
33. Duncan WC, Sarasso S, Ferrarelli F, et al,. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol, 2013; 16: 301-311.
34. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS, Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol, 2010; 13: 71-82.
35. Browne CA, Lucki I,. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol, 2013; 4: 161.
36. Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM,. Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry, 2012; 27: 974-980.
37. Ferguson JM, Shingleton RN,. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol, 2007; 30: 136-144.
38. Zarate CA Jr, Singh JB, Quiroz JA, et al,. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry, 2006; 163: 153-155.
39. Gideons ES, Kavalali ET, Monteggia LM,. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A, 2014; 111: 8649-8654.
40. Castren E, Rantamaki T,. Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment. CNS Drugs, 2010; 24: 1-7.
41. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A,. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol, 2013; 28: 87-90.
42. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ,. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F] altanserin positron emission tomography. Biol Psychiatry, 2004; 55: 217-224.
43. Shabel SJ, Proulx CD, Piriz J, Malinow R,. Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment. Science, 2014; 345: 1494-1498.
44. DeLorenzo C, DellaGioia N, Bloch M, et al,. In vivo ketamine-induced changes in [C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry, 2015; 77: 266-275.
45. Wolff K, Winstock AR,. Ketamine: from medicine to misuse. CNS Drugs, 2006; 20: 199-218.
46. Paul R, Schaaff N, Padberg F, Moller HJ, Frodl T,. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry, 2009; 10: 241-244.
47. Segmiller F, Ruther T, Linhardt A, et al,. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol, 2013; 53: 996-998.
48. Zhang JC, Li SX, Hashimoto K,. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav, 2014; 116: 137-141.
49. Burgdorf J, Zhang XL, Nicholson KL, et al,. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology, 2013; 38: 729-742.
50. Moskal JR, Burch R, Burgdorf JS, et al,. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs, 2014; 23: 243-254.
51. Schildkraut JJ,. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry, 1965; 122: 509-522.
52. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB,. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry, 2006; 59: 203-210.
53. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC,. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry, 2007; 62: 1217-1227.
54. Maeng S, Zarate CA Jr, Du J, et al,. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry, 2008; 63: 349-352.
55. Koike H, Iijima M, Chaki S,. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res, 2011; 224: 107-111.
56. Autry AE, Adachi M, Nosyreva E, et al,. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 2011; 475: 91-95.
57. Akinfiresoye L, Tizabi Y,. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology, 2013; 230: 291-298.
58. Duman RS, Monteggia LM,. A neurotrophic model for stress-related mood disorders. Biol Psychiatry, 2006; 59: 1116-1127.
59. Saarelainen T, Hendolin P, Lucas G, et al,. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci, 2003; 23: 349-357.
60. Monteggia LM, Luikart B, Barrot M, et al,. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry, 2007; 61: 187-197.
61. Ibarguen-Vargas Y, Surget A, Vourc'h P, et al,. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res, 2009; 202: 245-251.
62. Monteggia LM, Gideons E, Kavalali ET,. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry, 2013; 73: 1199-1203.
63. Titus MO, Eady M, King L, Bowman CM,. Effectiveness of a breath-actuated nebulizer device on asthma care in the pediatric emergency department. Clin Pediatr (Phila), 2012; 51: 1150-1154.
64. Inamura N, Nawa H, Takei N,. Enhancement of translation elongation in neurons by brain-derived neurotrophic factor: implications for mammalian target of rapamycin signaling. J Neurochem, 2005; 95: 1438-1445.
65. Klein PS, Melton DA,. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A, 1996; 93: 8455-8459.
66. Stambolic V, Ruel L, Woodgett JR,. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol, 1996; 6: 1664-1668.
67. Carvalho AF, Cavalcante JL, Castelo MS, Lima MC,. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther, 2007; 32: 415-428.
68. Bauer M, Adli M, Bschor T, et al,. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology, 2010; 62: 36-42.
69. Beurel E, Song L, Jope RS,. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry, 2011; 16: 1068-1070.
70. Hoshaw BA, Malberg JE, Lucki I,. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res, 2005; 1037: 204-208.
71. Jernigan CS, Goswami DB, Austin MC, et al,. The mTOR signaling pathway in the Rapid-onset prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2011; 35: 1774-1779.
72. Li N, Lee B, Liu RJ, et al,. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010; 329: 959-964.
73. Hay N, Sonenberg N,. Upstream and downstream of mTOR. Genes Dev, 2004; 18: 1926-1945.
74. Hoeffer CA, Klann E,. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci, 2010; 33: 67-75.